Project Africa GRADIENT (Genomic Research Approach for Diversity and Optimising Therapeutics) was initiated in 2018 as a collaboration between GSK and Novartis. The primary aim was to establish a consortium to collaborate with expert academic centers and organisations in Africa to support high quality research on African genetic diversity of relevance to drug therapeutics. The primary focus will be to evaluate genetic diversity as the contributing factor to variability in exposure, efficacy and/or safety to drugs used to treat tuberculosis (TB) and malaria in Africa. Project Africa GRADIENT aims to provide funding for up to 5 years, in two independent stages with the possibility of extensions. The RFA will be conducted in two phases. Phase 1 will be a Letter of intent submission and applicants successful during Phase 1 will progress to Phase 2 and invited to submit a full proposal.

The applicants will have the opportunity to apply for one of two initiatives:

• Fellowship for an individual researcher
• Investigator sponsored research

Eligibility

• This is an open call for proposals from researchers based at African (Northern, Western, Eastern, Central and Southern Africa) universities or institutions, science councils and other public research organizations.

Online intention to submit deadline: 01 March 2021

Visit Funder for more details